The Ultimate Directory on Pharmaceutical Webinars

Over the last years, there has been a growing development and use of liquid embolic agents in IR, enabling the treatment of more complex diseases such as vascular trauma and bleeding, arteriovenous malformations, aneurysms, meningiomas, and subdural hematomas – conditions that otherwise could not be effectively treated with other embolic devices. Despite their increasing prevalence, these agents remain underused or unavailable in some hospitals, limiting treatment options for complex diseases. Liquid embolic agents represent an advancement over traditional mechanical embolic materials, making it crucial for interventional radiologists to be proficient in their use within clinical practice.The webinar will highlight key embolic agents such as sclerosants, Gelfoam, glue, and polymers, delving into their physical properties, indications, technical considerations, efficacy, and the latest innovations.Learning objectives:• To understand the differences between different types of liquid embolic agents and their specific uses.• To learn about the main liquid embolic devices currently in use and their composition.• To understand the clinical applications of liquid embolic devices during elective procedures.• To learn how to use embolic devices during emergency procedures.Programme:Introduction by the moderator - Alessandro Cannavale (Rome/IT)Clinical assessment of patients undergoing embolization procedures - Andreas Mahnken (Marburg/DE)Overview of currently available and upcoming embolic agents - Enrique Esteban Hernandez (Valencia/ES)Sclerosant agents and challenging cases - Lakshmi Ratnam (London/UK)Glue and LIPIODOL and challenging cases - Alberto Alonso-Burgos (Madrid/ES)Polymers and challenging cases - Romaric Loffroy (Dijon/FR)Discussion and Q&ATake home points by the moderator - Carolina Lanza (Milan/IT)FacultyModerators:• Alessandro Cannavale (Rome/IT)• Carolina Lanza (Milan/IT)Speakers:• Alberto Alonso-Burgos (Madrid/ES)• Enrique Esteban Hernandez (Valencia/ES)• Romaric Loffroy (Dijon/FR)• Andreas Mahnken (Marburg/DE)• Lakshmi Ratnam (London/GB)

You're invited to join us for a powerful yarn with our panel of First Nations health leaders and advocates.This session is designed for pharmacy students, interns, and early career pharmacists to explore the health challenges Aboriginal and Torres Strait Islander peoples face—and why First Nations health is a responsibility we all share.Through an open and honest panel discussion, our speakers will reflect on the importance of cultural safety, the ongoing impacts of colonisation, and how pharmacists can make a real difference in their practice.This is a chance to listen, learn, and reflect as we work together towards health equity.Speakers: Shi-Anne Wallace, Indigenous Chair, National Australian Pharmacy Students’ Association; Samantha Kourtis, Community Pharmacist & Managing Partner, Capital Chemist Charnwood; Kelly Tanner, Indigenous Engagement Manager, The Pharmacy Guild of Australia; Lachlan Munns, President, Goorie Berrimpa (University of Queensland First Nations Student Association).

Explore the full journey of developing infectious disease lateral flow tests with experts from Lateral Dx and Medix Biochemica.Learn about critical stages in IVD development, strategies for optimizing antibody selection, and common pitfalls to avoid.Discover the real-world impact of infectious disease diagnostics on global health and see performance data from Medix Biochemica antibodies in action.After presentations, there's a Q & A session. Webinar is hosted by Anthony Austin.Date: Tuesday, May 13, 2025 Time and zone: 15:00 BST / 16:00 CEST / 10:00 EDT / 7:00 PDTDiscussion points:• Key stages of IVD test development: concept to validation• Challenges & pitfalls commonly experienced in assay development• Considerations in antibody selection and workflow efficiencies• Role of diagnostics in outbreak response• Real-world importance of accessible testing• Real and comparative data with Medix Biochemica antibodiesKey takeaways:• IVD test development requires careful planning at every stage• Antibody selection drives assay success• Common issues can be avoided early• Rapid diagnostics play a vital role in global health• Real-world data helps guide better antibody choices• Expert partnerships streamline developmentSpeakers and Host: Richard Campbell, Founder and Managing Director, Lateral DX; Amy Moore, Global Product Manager, Medix Biochemica; Anthony Austin, Global Marketing Manager, Medix Biochemica.

What is it all about?Thank you for your interest in Freyr’s Webinar Series (FWS)! We’re excited to have you join us on May 7, 2025, for an insightful session on “Demystifying Botanical Ingredients: An In-Depth Outlook in Europe.”Botanical ingredients play a key role in the European food supplement industry, offering numerous health and nutritional benefits. However, businesses face regulatory complexities due to fragmented national and EU-level guidelines. This webinar will explore:The current regulatory landscape for botanical ingredients in EuropeChallenges in placing botanical products on the marketKey EU and national regulations governing botanicalsThe responsibilities of Food Business Operators (FBOs) in ensuring product safetyReal-world examples of popular botanical ingredients and their regulatory conditionsBy the end of this session, you’ll have a clear understanding of the regulatory framework, compliance strategies, and market access pathways for botanical ingredients in Europe.Speakers: Meher Bhattiprolu, Manager - Global Regulatory Services, Food Products; Giulio Libertini, Deputy Manager - Regulatory Affairs (FDS).

The Access to Medicine Foundation is co-hosting a webinar on the 2024 Access to Medicine Index with Medicines Patent Pool (MPP) and the Ecumenical Pharmaceutical Network (EPN). The session will offer insights into industry trends, company-specific performances, and discuss strategies to enhance access to essential medicines in low- and middle-income countries.Access to medicine in sub-Saharan Africa remains a critical issue, with numerous barriers hindering equitable healthcare. The high cost of essential medicines is one of the main challenges in low- and middle-income countries (LMICs), creating a gap between the availability of these medicines and people's ability to afford them. To address this disparity and strengthen their collective efforts, the Access to Medicine Foundation, Medicines Patent Pool (MPP), and the Ecumenical Pharmaceutical Network (EPN) are partnering to host a joint webinar. The webinar will share key findings from the 2024 Access to Medicine Index and provide expert perspectives on the evolving landscape of access to medicine. During the webinar, the Foundation’s team will present detailed findings from the 2024 Index, including industry trends and company-specific performance. The team will emphasise the Index’s importance as a tool for accountability in the pharmaceutical sector. Following the presentation, the team will also engage in panel discussion and Q&A session, helping fellow attendees to delve deeper into the implications of the 2024 Index findings and exchange insights on the opportunities and challenges pharmaceutical companies face in advancing health equity and access in LMICs. 

While synthetic biology has considerably advanced in the past decade, cost continues to be a major factor in commercial viability. Saccharomyces cerevisiae is a commonly used microbial host in synthetic biology. These cultures can be grown to very high densities with high expression levels of target molecules, making S. cerevisiae a preferred candidate for cost-effective natural product synthesis.In this webinar, the expert speakers demonstrate the seamless scale-up of a high-yield fermentation process from 250 mL to 5 L, enabled by extensive vessel characterization using cloud-connected bioreactors. The speakers will share insights into how utilizing S. cerevisiae provided an efficient and cost-effective scale-up method.They will also present case studies that illustrate the steps taken to reduce costs and mitigate risks during the scale-up process. The attendees will also gain a comprehensive understanding of how cloud-connected bioreactors can dramatically accelerate the scale-up process in biomanufacturing. The speakers will then delve into practical troubleshooting methods, designed to address and overcome common challenges encountered during scale-up.Moreover, the session will explore effective strategies for reducing costs and de-risking the scale-up process, equipping attendees with tools and knowledge needed to optimize production efficiency and ensure successful outcomes in their biomanufacturing projects.Register for this webinar to discover how cloud-connected bioreactors are revolutionizing the scale-up process for biomanufacturing.What You Will LearnAttendees will learn about:• How cloud-connected bioreactors can accelerate scale-up• Troubleshooting methods to overcome scale-up challenges• Strategies for reducing costs and de-risking scale-upWho Should Attend?This webinar will appeal to:• Small-Mid-Large Biotech/Pharma• Emerging biotechs and startups/Agricultural biotechnology firms• Food Technology and fermentation-based food companies• Biofuel and renewable chemical companies• Research institutions and academia• Bioprocess Engineers• Head of Process Development/Innovation• Upstream Process Development Scientists• Formulation Scientists• Product Development• Consultants/R&D/Scientists/FormulatorsSpeakers: Andrew Horwitz, PhD, Vice President Research and Development, Inscripta; Kris Tyner, Senior Director, Bioprocess Sciences, Culture Biosciences.

ISAM is pleased to announce the next Webinar presented by Clair Brooks, Applications Specialist at Copley Scientific, Nottingham, England, UK. She will explore the latest advancements in nasal drug delivery, focusing on in-vitro testing methods and innovative tools for improved nasal deposition.Key points:• Utilising the intranasal route for systemic and nose-to brain drug delivery • Compendial in vitro testing requirements of nasal drug products • Challenges and developments in nasal testing• Studying nasal deposition with the Alberta Idealised Nasal Inlet and the Kiel Nasal InletNasal drug delivery presents a promising avenue for therapeutic administration, offering a non-invasive route that bypasses the gastrointestinal tract and hepatic first-pass metabolism. This method has become increasingly attractive for systemic drug administration, particularly for drugs that are poorly absorbed orally, as it utilises the highly vascularised and large surface area of the nasal mucosa for rapid absorption. Additionally, the permeability of the nasal mucosa and its nerve pathways are being utilised to achieve targeted drug delivery to the brain, effectively overcoming the blood-brain barrier. Rigorous testing is vital to ensure the safety, efficacy and quality of these products, and compendial in-vitro testing methods play a key role in evaluating product performance and ensuring compliance with regulatory standards. However, challenges remain in replicating physiological conditions and addressing patient-to-patient variability. Ongoing research and technological advancements continue to drive progress in this area, including the development of realistic nasal models to improve in vitro-in vivo correlations and automated device actuation to standardise dose delivery when evaluating bioequivalence. This webinar explores the advancements in in-vitro nasal testing and presents recent studies using two novel tools to look at nasal deposition.

This webinar will explore the applications of Dynamic Light Scattering (DLS) and Electrophoretic Light Scattering (ELS) in the pharmaceutical industry. The experts will also discuss how these techniques enhance drug formulation, stability, delivery, and improve the quality and efficacy of pharmaceutical products.Key Takeaways• Understanding the fundamentals of Dynamic Light Scattering (DLS) and Electrophoretic Light Scattering (ELS)• How particle size distribution and zeta potential impact pharmaceutical formulations and stability• Utilizing DLS and ELS to enhance drug delivery systems and improve pharmaceutical quality• Comprehensive understanding of BeNano’s advanced measurement capabilities for pharmaceutical applications.• Real-world case studies demonstrating BeNano’s applications in LNP, proteins, micelles, microemulsions, drug carriers, and Ag nanoparticles.Who Should Attend?This webinar will benefit beginners and professionals in research, development, processing or quality control who acquire understanding of comprehensive pharma characterization or who want to refresh and expand existing knowledge. Furthermore, those who are looking for suggestions for further possible uses of particle size characterization as well as stability of pharmaceutical suspensions should attend this webinar.Speakers: John F. Miller, PhD - Inventor of PALS; Zhibin Guo, MS - Senior Application Scientist.Register now to secure your spot!

The Inflation Reduction Act and the resulting Medicare Part D price negotiations are shaping up to be the most far reaching of any event impacting pharma manufacturing in recent history.Although the first set of negotiated prices for selected drugs will not take effect until January 1, 2026, the immediate impact has been fast and furious — more than a dozen lawsuits have been filed by pharmaceutical companies, advocacy groups and the US Chamber of Commerce. Industry media is ablaze with discussions on how price negotiations will impact the pricing of non-selected same-class drugs and biosimilars, as well as future drug development in general.With the first-round negotiated prices for selected drugs to be made public on September 1, 2024, companies are preparing themselves for the second round of selections. This timely webinar will provide an update on:To-date information on the legal actions, existing price negotiations, and market reactionsDrugs likely to be selected for the second round and their same-class competitors who will be impactedThe changes and impact of out-of-pocket costs on enrolleesPrice negotiation benchmarking on selected drugs compared to net pricing on competitorsHow manufacturers should prepare for the overall impact to the industryPart D plan utilization managementRegister for this webinar today to understand the profound impact of the Inflation Reduction Act and Medicare Part D price negotiations on the pharmaceutical industry.Speakers: Mark McCoy, RPh, MBA - Director, Client Engagement Pricing Market Access and Reimbursement, ICON; Amith Shetty, PharmD, RPh - Senior Clinical & Market Access Specialist, ICON; Dr. Xin Zhao - Principal, Global Market Access, ICON.Who Should Attend?This webinar will benefit pharmaceutical and biotech professionals in the following areas:Market access/Marketing/Managed markets/Market researchReal world evidenceRegulatory affairsChannel marketingClinical researchCompetitive intelligenceGovernment affairsHealth economics and outcomes researchWhat You Will LearnAttendees will learn about:The ongoing legal challenges initiated by pharmaceutical companies and other stakeholders against the Inflation Reduction Act’s price negotiation provisionsDrugs likely to be targeted in the upcoming rounds of Medicare Part D price negotiationsThe impact of changes to enrollees and drug manufacturers around reductions in patient out-of-pocket costsThe future impact on Part D plan utilization management

Join us for an informative webinar tailored for healthcare providers interested in understanding and recommending serum tears to their patients. Serum tears, derived from a patient’s own blood, offer a natural and personalized treatment option for chronic dry eye and other ocular surface diseases.Our featured presenter, Dr. Matthew Ward, a leading expert in the industry, will guide you through the science behind serum tears, their therapeutic benefits, and the process of preparing and prescribing them.Dr. Ward will cover:• The benefits of serum tears and the compounding process• The cost-effectiveness of serum tears as a treatment option for patients• The safety of serum tears as opposed to traditional eye drops and solutions• And so much more!This session will equip you with the knowledge and tools to confidently recommend serum tears, offering your patients a cutting-edge solution to manage their eye health.Who Should Attend:• Ophthalmologists• Optometrists• Primary care physicians• Healthcare providers involved in ocular care